CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...
In a 2025 JAMA Network Open invited commentary, Melina E. Marmarelis, MD, MSCE, and Lauren Reed-Guy, MD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...
Given the importance of pathologic examination in patients with resectable NSCLC, we do not consider ORR per RECIST to be a clinically relevant end point when pathologic stage and response are ...
Use of neoadjuvant or perioperative immunotherapy in combination with chemotherapy has proven effective for some patients with non-small cell lung cancer (NSCLC), but its role in patients with EGFR- ...
NeoADAURA: Can We Afford to Overlook Objective Response Rates? The following represents disclosure information provided by author of this manuscript. All relationships are considered compensated ...
FREMONT, Calif., September 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results